Abstract： Objective： To evaluate systematically the clinical efficacy of Bushen Huoxue Huayu therapy in the treatment of benign prostatic hyperplasia （BPH） by evidence-based medicine. Methods：Randomized controlled trials regarding Bushen Huoxue Huayu therapy for BPH were retrieved from China National Knowledge Infrastructure （CNKI）， Wanfang Data，VIP Database，SinoMed，Web of Science，The Cochrane Library，Embase，and PubMed from their inception to August 2025. Two reviewers independently screened the literature according to the inclusion and exclusion criteria and extracted the data； Meta-analysis was then performed with RevMan 5.4.1. Results： Nineteen studies involving 1 728 patients were included. Meta-analysis showed that the trial group exhibited higher total effective rate and maximum urinary flow rate（ Qmax） than the control group [OR=3.83，95%CI（ 2.78，5.27），P＜0.000 01；MD=2.52， 95%CI （1.53， 3.50）， P＜0.000 01]， and lower International Prostate Symptom Score （IPSS）， post-void residual urine volume （PVR），prostate volume （PV），and quality-of-life index （QOL） scores [MD=-3.72，95%CI （-4.40， -3.05），P＜0.000 01；MD=-6.71，95%CI （-8.59，-4.83），P＜0.000 01；MD=-3.07，95%CI （-4.56，-1.57）， P＜0.000 1； MD=-0.86， 95%CI （-1.07， -0.64）， P＜0.000 01]. Conclusion： Bushen Huoxue Huayu therapy is superior to conventional western medicine alone in improving total effective rate and Qmax， and in reducing IPSS， PVR，PV，and QOL scores for patients with BPH.